Geron (GERN)

• Market cap: $810M
• 1 day: 0%
• 5 days: -7.3%
• 1 month: -12.41%
• 3 months: -18.06%
• 6 months: -27.01%
• Year to date: -64.72%
• 1 year: -70.94%
• 5 years: -31.35%
• 10 years: -64.23%
• Sector: Healthcare
• Industry: Biotechnology

About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Employees: 229

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

40% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 70

28% more call options, than puts

Call options by funds: $1.31M | Put options by funds: $1.02M

0.73% more ownership

Funds ownership: 80.04% [Q1] → 80.77% (+0.73%) [Q2]

6% less funds holding

Funds holding: 270 [Q1] → 255 (-15) [Q2]

11% less capital invested

Capital invested by funds: $812M [Q1] → $726M (-$86M) [Q2]

28% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 40

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1
• Avg. target: $1
• High target: $1

1 analyst rating

• positive: 0 0%
• neutral: 0 0%
• negative: 1 100%

Goldman Sachs Corinne Jenkins

$1

Sell Reinstated

10 Jul 2025